

DAFTAR PUSTAKA

- Abalos E., Cuesta C., Grosso D., and Chou L. 2013. Global and regional estimates of preeclampsia and eclampsia: a systematic review. *Eur J Obstet Gynecol Reprod Biol.* 170:1–7.
- Aggarwal PK., Chandel N., Jain V., and Jha V. 2011. The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. *J Hum Hypertens.* 26:236-241.
- Alves MJ, and Colli W. 2006. Animal experimentation: A controversy about the scientific work. *Ienc Hoje.* 39:24–29.
- Andraweera PH., Dekker GA., and Roberts CT. 2012. The vascular endothelial growth factor family in adverse pregnancy outcomes. *Hum Reprod Update.* 18(4):436-457.
- Badan Pusat Statistik. 2012. Survei demografi dan kesehatan indonesia (SDKI). Badan Pusat Statistik. Jakarta.
- Bahlmann F., and Naimi AA. 2016. Using the angiogenic factors sFlt-1 and PlGF with Doppler ultrasound of the uterine artery for confirming preeclampsia. *Arch Gynecol Obstet.* 294:1133–1139.
- Barton JR. 2012. A Push to End Preeclampsia. *ACOG online.* Home page on-line. Tersedia pada <http://www.acog.org/>. Diakses tanggal 25 Agustus 2016 pukul 08.00 WIB.
- Bartsch E., Medcalf K., Park AL., and Ray JG. 2016. Clinical risk factors for preeclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *BMJ.* 353:i1753.
- Baschat AA., Magder LS., Doyle LE., Atlas RO., Jenkins CB., and Blitzer MG. 2014. Prediction of preeclampsia utilizing the first trimester screening examination. *Am J Obstet Gynecol.* 211(5):514.e1-7.
- Bdolah Y., Elchalal U., Natanson-Yaron S., Yechiam H., Bdolah-Abram., Greenfield C., *et al.* 2014. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. *Hypertens Pregnancy.* 33:250–259.
- Bdolah Y., Lam C., Rajakumar A., Shivalingappa V., Mutter W., Sachs BP *et al.* 2008. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? *Am J Obstet Gynecol.* 198:428.e1–6.
- Benirschke K., Burton GJ., and Baergen RN. 2012. *Pathology of the Human Placenta.* 6th Ed. Springer: New York.

- Benzing T. 2016. Testing for preeclampsia: paving the way to early diagnosis. *Nat Rev Nephrol.* 12:200-202.
- Bian Y., Zhang Z., Liu Q., and Wang S. 2013. Maternal risk factors for low birth weight for term births in a developed region in China: a hospital-based study of 55.633 pregnancies. *J Biomed Res.* 27(1):14-22.
- Bilano VL., Ota E., Ganchimeg T., Mori R., and Souza JP. 2014. Risk factors of pre-eclampsia/eclampsia and its adverse outcomes in low- and middle-income countries: A WHO secondary analysis. *PloS ONE.* 9(3):e91198.
- Bose C., Van Marter LJ., Laughon M. O'Shea TM., Allred EN., Karna P., *et al.* 2009. Fetal growth restriction and chronic lung disease among infants born before the 28th week of gestation. *Pediatrics.* 124 (3):e450-e458.
- Buhimschi CS., Magloire L., Funai E., Norwitz ER., Kuczynski E., Martin R., *et al.* 2006. Fractional excretion of angiogenic factors in women with severe preeclampsia. *Obstet Gynecol.* 107: 1103–1113.
- Burke SD., Zsengeller ZK., Khankin EV., Lo AS., Rajakumar A., DuPont JJ., *et al.* 2016. Soluble fms-like tyrosine kinase 1 promotes angiotensin II sensitivity in preeclampsia. *J Clin Invest.* 126(7): 2561-2574.
- Burton GJ., Woods AW., Jauniaux E., and Kingdom JC. 2009. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. *Placenta.* 30:473-482.
- Caluwaerts S., Vercruyse L., Luyten C., and Pijneborg R. 2005. Endovascular trophoblast invasion and associated structural changes in uterine spiral arteries of the pregnant rat. *Placenta.* 26:574-584.
- Carolan M. 2013. Maternal age \geq 45 years and maternal and perinatal outcomes: a review of the evidence. *Midwifery.* 29:479–489.
- Carty DM., and Dominiczak AF. 2010. Preeclampsia and future maternal health. *J Hypertens.* 28(7):1349-1355.
- Cayman Chemical Company. 2016. L-NAME information sheet. Caymanchem *online.* Home page on-line. Tersedia pada <https://www.caymanchem.com>. Diakses tanggal 19 September 2016 pukul 13.00 WIB.
- Cerdeira AN., and Karumanchi SA. 2012. Angiogenic factors in preeclampsia and related disorders. *Cold Spring Harb Perspect Med.* 2(11): a006585.
- Chaiworapongsa T., Romero R., Espinoza J., Bujold E., Kim MY., Goncalves LF., *et al.* 2004. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. *Am J Obstet Gynecol* 190: 1541-1550.

- Chappell LC., Enye S., Seed P., Briley AL., Poston L., and Shennan AH. 2008. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. *Hypertension*. 51(4):1002–1009.
- Christine K., Ratajczak., Fay JC., Louis J., and Muglia. 2010. Preventing preterm birth: the past limitations and new potential of animal models. *Dis Models Mech*. 3:407-414.
- Ciarmela P., Boschi S., Bloise E., Marozio L., Benedetto C., Castellucci M., *et al*. 2010. Polymorphisms of FAS and FAS ligand genes in preeclamptic women. *Eur J Obstet Gynecol Reprod Biol*. 148:144-146.
- Conde-Agudelo A., Papageorgiou AT., Kennedy SH., and Villar J. 2013. Novel biomarkers for predicting intrauterine growth restriction: a systematic review and meta-analysis. *BJOG*. 120(6):681-694.
- Craici IM., Wagner SJ., Weissgerber TL., Grande JP., and Garovic VD. 2014. Advances in the pathophysiology of pre-eclampsia and related podocyte injury. *Kidney Int*. 86 (2): 275-285.
- Crispi F., Dominguez C., Llurba E., Martin-Gallan P., Cabero L., and Gratacos E. 2006. Placental angiogenic growth factors and uterine artery Doppler findings for characterization of different subsets in preeclampsia and in isolated intrauterine growth restriction. *Am J Obstet Gynecol*. 195: 201–207.
- Czech DA., Kazel MR., and Harris J. 2003. A nitric oxide synthase inhibitor, N(G)-nitro-L-arginine methyl ester, attenuates lipoprivic feeding in mice. *Physiol Behav*. 80:75-79.
- D’Amico G., and Bazzi C. 2003. Pathophysiology of proteinuria. *Kidney Int*. 63(3): 809-825.
- Davies TC., Sanders DA., Burton GJ., and Jones SC. 2011. Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling. *Cardiovasc Res*. 89 (3): 671-679.
- De Luca B., Monda M., and Sullo A. 1995. Changes in eating behavior and thermogenic activity following inhibition of nitric oxide formation. *Am J Physiol*. 268: R1533-R1538.
- Departemen Kesehatan Republik Indonesia. 2013. Profil Kesehatan Indonesia. Jakarta: Depkes RI.
- Dong W., Xu QX., Han YH., and Yin LR. 2011. Inhibitory effects of soluble endoglin on invasive ability of cultured cytotrophoblasts of first trimester of pregnancy. *Sheng Li Xue Bao*. 63 (3):267-271.

- Ducommun D. 2017. Rat Reproduction: Mating, gestation, birthing, and growth. <http://www.peteducation.com>. Diakses tanggal 26 Mei 2017 pukul 18.00 WIB.
- Duley L. 2009. The global impact of preeclampsia and eclampsia. *Semin perinatol.* 33(3): 130-137.
- Duwel A., Eleno N., Jerkic M., Arevalo M., Bolanos JP., Bernabeu C., *et al.* 2007. Reduced tumor growth and angiogenesis in endoglin haplo insufficient mice. *Tumour Biol.* 28:1–8.
- Eremina V., Baelde HJ., and Quaggin SE. 2007. Role of the VEGF-A signaling pathway in the glomerulus: evidence for crosstalk between components of the glomerular filtration barrier. *Nephron Physiol.* 106(2): p32–p37.
- Eremina V., Jefferson JA., Kowalewska J., Hochster H., Haas M., Weisstuch J., *et al.* 2008. VEGF inhibition and renal thrombotic microangiopathy. *N Engl J Med.* 358:1129-1136.
- Fan L., Wakayama T., Yokoyama S., Amano O., and Iseki S. 2002. Downregulation of vascular endothelial growth factor and its receptors in the kidney in rats with puromycin aminonucleoside nephrosis. *Nephron.* 90(1):95–102.
- Fan Q., Xing Y., Ding J., and Guan N. 2009. Reduction in VEGF protein and phosphorylated nephrin associated with proteinuria in adriamycin nephropathy rats. *Nephron Exp Nephrol.* 111(4):e92–e102.
- Fan X., Rai A., Kambham N., Sung JF., Singh N., and Petitt M. 2014. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. *J Clin Invest.* 124:4941–4952.
- Federer WT. 1991. *Statistics and society: Data collection and Interpretation*, 2nd Ed. NY: Marcel dekker, Inc. 142.
- Ferrara N. 2004. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev.* 25: 581–611.
- Festing S., and Wilkinson R. 2007. The ethics of animal research. Talking Point on the use of animals in scientific research. *EMBO Reports.* 8(6):526-530.
- Fonseca BM., Silva GC., and Teixeira NA. 2011. The rat as an animal model for fetoplacental development: a reappraisal of the post-implantation period. *Reprod biol.* 12(2): 97-118.
- Furukawa S., Hayashi S., Usuda K., Abe M., Hagio S., and Ogawa I. 2011. Toxicological pathology in the rat placenta. *J Toxicol Pathol.* 24:95-111.
- Gardiner C., Tannetta DS., Simms CA., Harrison P., Redman CW., and Sargent IL. 2011. Syncytiotrophoblast microvesicles released from pre-eclampsia placentae exhibit increased tissue factor activity. *PLoS One.* 6(10):e26313.

- Gifford RW., August PA., and Cunningham FG. Report of the national high blood pressure working group on research on hypertension in pregnancy. *Am J Obstet Gynecol.* 2000;183:S1–S22.
- Gilbert JS., Gilbert SA., Arany M., and Granger JP. 2009. Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. *Hypertension.* 53:399-403.
- Goetzinger KR., Tuuli MG., Cahill AG., Macones GA., and Odibo AO. 2015. Development and validation of a risk factor scoring system for first-trimester prediction of pre-eclampsia. *Am J Perinatol.* 31(12): 1049–1056.
- Gregory Al., Xu G., Sotov., and Letarte. 2014. The enigmatic role of endoglin in the placenta. *Placenta.* 28: S93-S99.
- Gu Y., Lewis DF., and Wang Y. 2008. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. *J Clin Endocrinol Metab.* 93(1): 260-266.
- Han C., Zhao Q., and Lu B. 2013. The role of nitric oxide signaling in food intake; insights from the inner mitochondrial membrane peptidase 2 mutant mice. *Redox Biology.* 1(1): 498-507.
- Han YW., Zang Z., Ding XY., and Yu H. 2015. Differences in liver injury and trophoblastic mitochondrial damage in different preeclampsia-like mouse models. *Chin Med J (Engl).* 128(12): 1627–1635.
- Hansson HR., Nääv A., and Erlandsson R. 2015. Oxidative stress in preeclampsia and the role of free fetal hemoglobin. *Front Physiol.* 5:516.
- Harris LK. 2011. IFPA Gabor Than Award lecture: transformation of the spiral arteries in human pregnancy: key events in the remodelling timeline. *Placenta.* Suppl 2:S154-158.
- Hawinkels LJ., Kuiper P., Wiercinska E., Verspaget HW., Liu Z., Pardali E., *et al.* 2010. Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis. *Cancer Res.* 70 (10): 4141-4150.
- Hirashima C., Ohkuchi A., Matsubara S., Suzuki H., Takahashi K., Usui R., and Suzuki M. 2008. Alteration of serum endoglin levels after the onset of preeclampsia is more pronounced in women with early-onset. *Hypertens Res.* 31 (8): 1541-1547.
- Hodges JB, 2010. Mating: Rat breeding guide. Ratguide *online*. Home page online. Tersedia pada <http://ratguide.com/>. Diakses tanggal 24 November 2016 pukul 10.00 WIB.

- Hsu P., and Nanan RK. 2014. Innate and adaptive immune interactions at the fetal-maternal interface in healthy human pregnancy and pre-eclampsia. *Front Immunol.* 5:125.
- Huckle WR., and Roche RI. 2004. Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor. *J Cell Biochem.* 93(1): 120–132.
- Irimie MI., Vu HV., Whitbred JM., Pridjian CA., Nadig JD., Williams MY., *et al* 2005. A rat model of preeclampsia. *Clin Exp Hypertens.* 8:605–617.
- ISSHC, 2014. The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the ISSHP. *Pregnancy Hypertens.* 4:97-104.
- Jahan M., Hasanuzzaman M., Mahbuba S., Jahan H., Chowdhury S., Ahsan GU., *et al.* 2015. Prevalence of preeclampsia in pre-gestational diabetic pregnancy in Bangladeshi patients. *Pregnancy Hypertens.* 5: 113 – 114.
- Jain L. 2008. Respiratory morbidity in late-preterm infants: prevention is better than cure! *Am J Perinatol.* 25 (2): 75-78.
- Jerkic M., Rodriguez-Barbero A., Prieto M., Toporsian M., Pericacho M., Rivas-Elena JV *et al.* 2006. Reduced angiogenic responses in adult endoglin heterozygous mice. *Cardiovasc Res.* 69:845–854.
- Jeyabalan A. 2013. Epidemiologi of preeclampsia: Impact of obesity. *Nutr Rev.* 71 (01):S18-S25.
- Kaitu'u-Lino TJ., Palmer KR., Whitehead CL., Williams E., Lappas M., and Tong S. 2012. MMP-14 is expressed in preeclamptic placentas and mediates release of soluble endoglin. *Am J Pathol.* 180(3): 888-894.
- Kammerman P., Mitchell D., and Laburn H. 2002. Circadian variation in the effects of nitric oxide synthase inhibitors on body temperature, feeding and activity in rats. *Eur J Physiol.* 443:609-616.
- Kamoun WS., Karaa A., Kresge N., Merkel SM., and Clemens MG. 2006. LPS inhibits endothelin-1- induced endothelial NOS activation in hepatic sinusoidal cells through a negative feedback involving caveolin-1. *Hepatology.* 43:182–190.
- Kar M. 2014. Role of biomarkers in early detection of preeclampsia. *J Clin Diagn Res.* 8(4): BE01–BE04.
- Kaya A., Boztosun A., Seckin H., Guven AS., Kucukdurmaz Z., Gulturk S., and Cevit O. 2011. The evaluation of hypoxia-inducible factor 1 in N-nitro-L-arginine methyl ester preeclampsia model of pregnant rats. *J Investig Med.* 59 (8): 1268-1272.

- Khan MS., Tachibana T., Hasebe Y., Masuda N., and Ueda H. 2007. Peripheral or central administration of nitric oxide synthase inhibitor affects feeding behavior in chicks. *Comp Biochem Physiol A Mol Integr Physiol.* 148 (2):458-462.
- Khowaja AR., Mitton C., Bryan S., Magee LA., Bhutta Z A., and von Dadelszen P. 2015. Economic evaluation of community level interventions for pre-eclampsia (CLIP) in South Asian and African countries: a study protocol. *Implement. Sci.* 10: 76.
- Koch S., and Welsh LC. 2012. Signal transduction by vascular endothelial growth factor receptors. *Cold Spring Harb Perspect Med.* 2(7): a006502.
- Lam C., Lim KH., and Karumanchi. 2005. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. *J Am Heart Assoc.* 46:1077-1085.
- Lambert G., Brichant JF., Hartstein G., Bonhomme V., and Dewandre PY. 2014. Preeclampsia: an update. *Acta Anaesthesiol Belg.* 65 (4): 137-149.
- Lecarpentier E., and Tsatsaris V. 2016. Angiogenic balance (sFlt-1/PlGF) and preeclampsia. *Ann Endocrinol.* 77 (2): 97-100.
- Levine RJ., Lam C., Qian C., Yu KF., Maynard SE., Sachs BP., Sibai BM., Epstein FH., and Romero R. 2006. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. *N Engl J Med.* 355:992-1005.
- Levine RJ., Maynard SE., Qian C., Lim KH., England LJ., and Yu KF. 2004. Circulating angiogenic factors and the risk of preeclampsia. *N Engl J Med.* 350:672–683.
- Li DY., Sorensen LK., Brooke BS., Urness LD., Davis EC., Taylor DG *et al.* 1999. Defective angiogenesis in mice lacking endoglin. *Science.* 284:1534-1537.
- Lisette C., Prada CE., Medina CER., and Lopez M. 2014. Endothelial dysfunction and preeclampsia: Role of oxidative stress. *Front Physiol.* 5(372):372.
- Loomis ED., Sullivan JC., Osmond DA., Pollock DM., and Pollock JS. 2005. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. *J Pharmacol Exp Ther.* 315:1058–1064.
- López NJM. 2007. Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia. *Nephrol Dial Transplant.* 22:712-714.
- Lopez NJM., and Bernabeu C. 2010. The physiological role of endoglin in the cardiovascular system. *Am J Physiol Heart Circ Physiol.* 299(4):H959-974.

- Luft FC. 2006. Soluble endoglin (sEng) joins the soluble fms-like tyrosine kinase (sFlt) receptor as a pre-eclampsia molecule. *Nephrol Dial Transplant*. 21(11):3052 -3054.
- Lyll F., Robson SC., and Bulmer. 2013. Spiral artery remodelling and trophoblast invasion in preeclampsia and fetal growth restriction: relationship to clinical outcome. *Hypertension*. 62(6):1046-1054.
- Lynch AM., and Salmon JE. 2010. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. *Placenta*. 31(7):561-567.
- Lynge Nilsson L., Djuricic S., and Hviid TV. 2014. Controlling the immunological crosstalk during conception and pregnancy: HLA-G in reproduction. *Front Immunol*. 5:198.
- Maharaj AS., Walshe TE., Saint-Geniez M, Venkatesha S, Maldonado AE, and Himes NC. 2008. VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. *J Exp Med*. 205: 491–501.
- Mahmoud M., Uptont PD., and Arthur HM. 2011. Angiogenesis regulation by TGFβ signalling: clues from an inherited vascular disease. *Biochem Soc Trans*. 39:1659–1666.
- Masuyama H., Nakatsukasa H., Takamoto N., and Hiramatsu Y. 2007. Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia. *J Clin Endocrinol Metab*. 92 (7): 2672–2679.
- Matsuo K., Kooshesh S., Dinc M., Sun CC., Kimura T., and Baschat AA. 2007. Late postpartum eclampsia: report of two cases managed by uterine curettage and review of the literature. *Am J Perinatol*. 24: 257–266.
- Maynard S., Epstein FH., and Karumanchi SA. 2008. Preeclampsia and angiogenic imbalance. *Annu Rev Med*. 59: 61-78.
- Maynard SE., Min JY., Merchan J., Lim KH., Li J., Mondal S., Libermann TA., Morgan JP., Sellke FW., Stillman IE., *et al*. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J Clin Invest*. 111 (5): 649-658.
- McClure EM., Saleem S., Pasha O., and Goldenberg RL. 2009. Stillbirth in developing countries: A review of causes, risk factors and prevention strategies. *J Matern Fetal Neonatal Med*. 22:183-90.
- Morley JE., Farr SA., Sell RL., Hileman SM., and Banks WA. Nitric oxide is a central component in neuropeptide regulation of appetite. *Peptides*. 32 (4):776-780.

- Mosca L., Benjamin EJ., Berra K., Bezanson JL., Dolor RJ., Lloyd-Jones DM *et al.* 2011. Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. *J Am Coll Cardiol.* 57 (12): 1404-1423.
- Murphy MS, and Smith GN. 2016. Pre-eclampsia and cardiovascular disease risk assessment in women. *Am J Perinatol.* 33 (8): 723-731.
- Myatt L., and Webster RP. 2009. Vascular biology of preeclampsia. *J Thromb Haemost.* 7: 375-384.
- Naljayan MV., and Karumanchi SA. 2013. New developments in the pathogenesis of preeclampsia. *Adv Chronic Kidney Dis.* 20(3):265-270.
- Ogge G., Romero R., Kusanovic JP., Chaiworapongsa T., Dong Z., Mittal P., *et al.* 2010. Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice. *J Matern Fetal Neonatal Med.* 23: 820–827.
- Osungbade KO., and Ige OK. 2011. Public health perspectives of preeclampsia in developing countries: Implication for health system strengthening. *J Pregnancy.* 2011: 481095.
- Oujo B., Perez-Barriocanal F., Bernabeu C., and Lopez NJM. 2013. Membrane and soluble forms of endoglin in preeclampsia. *Curr Mol Med.* 13(8):1345-1357.
- Parasuraman S., Raveendran R., and Kesavan R. 2010. Blood sample collection in small laboratory animals. *J Pharmacology & Pharmacother.* 1(2): 87-93.
- Pellicer B., Herraiz S., Leal A., Simon C., Pellicer A. 2011. Prenatal brain damage in preeclamptic animal model induced by gestational nitric oxide synthase inhibition. *J Pregnancy.* Article ID 809569.
- Pitakkarnkul S., Phaloprakarn C., Wiriyasirivaj B., Manusirivithaya S., and Tangjitgamol S. 2011. Seasonal variation in the prevalence of preeclampsia. *J Med Assoc Thai.* 94: 1293 – 1298.
- Potenza MA., Gagliardi S., Nacci C., Carratu MR., and Montagnani M. 2009. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. *Curr Med Chem.* 16:94-112.
- Quinn R. 2005. Comparing rat's to human's age: How old is my rat in people years? *Nutrition.* 21:775–777.
- Rajakumar A., Michael HM., Rajakumar PA., Shibata E., Hubel CA., Karumanchi SA., *et al.* 2005. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood

mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. *Placenta*. 26:563–573.

Ramma W., and Ahmed A. 2011. Is inflammation the cause of pre-eclampsia? *Biochem Soc Trans*. 39: 1619–1627.

Ramma W., Buhimschi IA., Zhao G., Dulay AT., Nayeri UA., Buhimschi CS., *et al.* 2012. The elevation in circulating anti-angiogenic factors is independent of markers of neutrophil activation in preeclampsia. *Angiogenesis*. 15: 341–348.

Ramzy D., Rao V., Tumiati LC., Sheshgiri R., Miriuka S., Delgado DH., *et al.* 2006. Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway. *Circulation*. 114:I319–I326.

Rana S., Karumanchi SA., and Lindheimer MD. 2014. Angiogenic factors in diagnosis, management, and research in preeclampsia. *Hypertension*. 63: 198–202.

Rathouska J., Jezkova K., Nemeckova I., Nachtiqal P. 2015. Soluble endoglin, hypercholesterolemia and endothelial dysfunction. *Atherosclerosis*. 243(2): 383-388.

Rätsep MT., Felker AM., Kay VR., Tolusso L., Hofmann AP., and Croy BA. 2015. Uterine natural killer cells: supervisors of vasculature construction in early decidua basalis. *Reproduction*. 149(2): R91-R102.

Roberts JM., and Escudero C. 2012. The placenta in preeclampsia. *Pregnancy Hypertens*. 2: 72-83.

Robinson CJ., and Johnson DD. 2007. Soluble endoglin as a second-trimester marker for preeclampsia. *Am J Obstet Gynecol*. 197(2):174.e1-5.

Sachs N., and Sonnenberg A. 2013. Cell-matrix adhesion of podocytes in physiology and disease. *Nat Rev Nephrol*. 9(4):200 -210.

Saito S., and Nakashima A. 2014. A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodelling. *J Reprod Immunol*. 101-102: 80-88.

Salahuddin S., Lee Y., Vadnais M., Sachs BP., Karumanchi SA., and Lim KH. 2007. Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. *Am J Obstet Gynecol*. 197: 28.e1–28.e6.

Sanchez ET., Botella LM., Velasco B., Langa C., and Bernabeu C. 2002. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor -beta pathways. *J Biol Chem*. 277(46):43799-43808.

- Santibanez JF., Letamendia A., Perez-Barriocanal F., Silvestri C., Saura M., Vary CP., Lopez NJM *et al.* 2007. Endoglin increases eNOS expression by modulating smad2 protein levels and smad2-dependent TGF beta signalling. *J Cell Physiol.* 210 (2): 456-468.
- Satchell SC., and Braet F. 2009. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. *Am J Physiol Renal Physiol.* 296(5): F947–F956.
- Sedlmayr P., Blaschitz A., and Stocker R. 2014. The role of placental tryptophan catabolism. *Front Immunol.* 5:230.
- Sengupta P. 2012(a). Challenge of infertility: How protective the yoga therapy is? *Anc Sci Life.* 32:61–62.
- Sengupta P. 2012(b). A scientific review of age determination for a laboratory rat: How old is it in comparison with human age? *Biomed Int.* 2:81–89.
- Sengupta P. 2012(c). Health impacts of yoga and pranayama: A state-of-the-art review. *Int J Prev Med.* 3:444–458.
- Sengupta P. 2013. The laboratory rat: Relating its age with human's. *Int J Prev Med.* 4(6):624-630.
- Shah A., Fawole B., M'imunya JM., Amokrane F., Nafiou I., Wolomby JJ., *et al.* 2009. Ceasarean delivery outcomes from the WHO global survey on maternal and perinatal health in Africa. *Int J Gynaecol Obstet.* 107:191-197.
- Shibuya M. 2013. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. *J Biochem.* 153(1): 13-19.
- Shrivastava S., Ansari AS., and Lohiya NK. 2011. Fertility, developmental toxicity and teratogenicity in albino rats treated with methanol sub-fraction of Carica papaya seeds. *Indian J Pharmacol.* 43(4):419-423.
- Srinivas SK. Edlow AG., Neff PM., Sammmel MD., Andrela Cm., and Elovitz MA. 2009. Rethinking IUGR in preeclampsia: dependent or independent of maternal hypertension? *J Perinatol.* 29(10):680-684.
- Staff AC., Braekke K., Johnsen GM., Karumanchi SA., and Harsem NK. 2007. Circulating concentrations of soluble endoglin (CD105) in fetal and maternal serum and in amniotic fluid in preeclampsia. *Am J Obstet Gynecol.* 197 (2): 176.e1-e6.
- Szalai G., Romero R., Chaiworapongsa T., Xu Y., Wang B., Ahn HY. 2015. Full-Length Human Placental sFlt-1-e15a Isoform Induces Distinct Maternal Phenotypes of Preeclampsia in Mice. *PLoS ONE.* 10 (4): e0119547.

- Taddei S., Ghiadoni L., Virdis A., Versari D., and Salvetti A. 2003. Mechanisms of endothelial dysfunction: clinical significance and preventive non pharmacological therapeutic strategies. *Curr Pharm.* 9:2385-2402.
- Tammela T., Zarkada G., Wallgard E., Murtomaki A., Suchting S., Wirzenius M *et al.* 2008. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. *Nature.* 454:656-660.
- Tannetta D., and Sargent I. 2013. Placental disease and the maternal syndrome of preeclampsia: Missing links? *Curr Hypertens Rep.* 15(6): 590-599.
- Than NG., Balogh A., Romero R., Kárpáti E., Erez O., Szilágyi A., Kovalszky I *et al.* 2014. Placental Protein 13 (PP13) - a placental immunoregulatory galectin protecting pregnancy. *Front Immunol.* 5:348.
- Thomas CP, Andrews JI, Liu KZ 2007. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. *FASEB J.* 21(14): 3885–3895.
- Thornton C., Dahlen H., Korda A., and Hennessy A. 2013. The incidence of preeclampsia and eclampsia and associated maternal mortality in Australia from population-linked datasets: 2000-2008. *Am J Obstet Gynecol.* 208 (6): 476.e1-5.
- Toblli JE., Bevione P., Gennaro FD., Madalena L., Cao G., Angerosa M. 2012. Understanding the mechanisms of proteinuria: Therapeutic implications (Review Article). *Int J Nephrol.* Article ID 546039.
- Toporsian M., Gros R., Kabir MG., Vera S., Govindaraju K., and Eidelman DH. 2005. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. *Circ Res.* 96:684-692.
- Trifonova EA., Gabidulina TV., Ershov NI., Serebrova VN., Vorozhishcheva AY., and Stepanov VA. 2014. Analysis of the placental tissue transcriptome of normal and preeclampsia complicated pregnancies. *Acta Naturae.* 6:71–83.
- Trogstad L., Magnus P., and Stoltenberg C. 2011. Pre-eclampsia: risk factors and causal models. *Best Pract Res Clin Obstet Gynaecol.* 25:329–342.
- Tsatsaris V., Goffin F., Munaut C., Brichant JF., Pignon MR., and Noel A. 2003. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. *J Clin Endocrinol Metab.* 88: 5555–5563.
- Tsuchiya K, Sakai H , Suzuki N., Iwashima F., Yoshimoto T., Shichiri M., and Hirata Y. 2007. Chronic blockade of nitric oxide synthesis reduces adiposity and improves insulin resistance in high fat-induced obese mice. *Endocrinology.* 148 (10): 4548-4556.

- Uzan J., Carbonnel M., Piconne O., Asmar R., and Ayoubi JM. 2011. Pre-eclampsia: pathophysiology, diagnosis, and management. *Vasc Health Risk Manag.* 7: 467–474.
- Venkatesha S., Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM *et al.* 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia. *Nat Med.* 12:642–649.
- Verlohren S., Geusens N., Morton J., Verhaegen I., Hering L., Herse F *et al.* 2010. Inhibition of trophoblast-induced spiral artery remodelling reduces placental perfusion in rat pregnancy. *Hypertension.* 56: 304-310.
- Wallis AB., Saftlas AF., Hsia J., and Atrash HK. 2008. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. *Am J Hypertens.* 21:521-526.
- Walshe TE., Dole VS., Maharaj AS., Patten IS., Wagner DD., and D'Amore PA. 2009. Inhibition of VEGF or TGF- β signalling activates endothelium and increases leukocyte rolling. *Arterioscler Thromb Vasc Biol.* 29:1185-1192.
- Walshe TE., Saint-Geniez M., Maharaj AS., Sekiyama E., Maldonado AE., and D'Amore PA. 2009. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. *PLoS ONE.* 4:e5149.
- Wathen KA., Tuutti E., Stenman UH., Alfthan H., Halmesmaki E., Finne P., Ylikorkala O., and Vuorela P. 2006. Maternal serum-soluble vascular endothelial growth factor receptor-1 in early pregnancy ending in preeclampsia or intrauterine growth retardation. *J Clin Endocrinol Metab.* 91: 180-184.
- WHO. Make every mother and child count in. *The world health report 2005.* Geneva, Switzerland: World Health Organization.
- Woolcock J., Hennessy A, Xu B., Thornton ., Tooher J., Makris A., *et al.* 2008. Soluble Flt-1 as a diagnostic marker of pre-eclampsia. *Aust N Z J Obstet Gynaecol.* 48(1):64-70.
- World Health Organization. 2014. Maternal mortality *fact sheet.* WHO online. Home page on-line. Tersedia pada <http://www.who.int/en/>. Diakses tanggal 25 Agustus 2016 pukul 08.00 WIB.
- Xiao R., Sorensen TK., Williams MA., and Luthy DA. 2003. Influence of pre-eclampsia on fetal growth. *J Matern Fetal Neonatal Med.* 13(3):157-162.
- Young BC., Levine RJ., and Karumanchi SA. 2010. Pathogenesis of preeclampsia. *Annu Rev Pathol.* 5:173–192.



UNIVERSITAS
GADJAH MADA

KADAR SOLUBLE FMS-LIKE TYROSINE KINASE-1 (SFLT-1) DAN SOLUBLE ENDOGLIN (SENG) PADA TIKUS WISTAR (RATTUS NOVERGICUS) NORMOTENSI DAN MODEL PREEKLAMPSIA YANG DIINDUKSI N-Nitro-L-arginine methyl ester (L-NAME)

ANDI FITRIANI KUSUMA, Dr. dr. Dicky Moch. Rizal, M.Kes., Sp.And.; Prof. dr. Moh. Hakimi, PhD., Sp. OG (K)
Universitas Gadjah Mada, 2017 | Diunduh dari <http://etd.repository.ugm.ac.id/>

Zadeh NM., Naghshvar F., Peyvandi S., Gheshlaghi P., and Ehetshami S. 2012. PP13 and PAPP-A in the first and second trimesters: Predictive factors for preeclampsia?. *International Scholarly Research Network*, vol.2012.

Zeisler H., Llurba E., Chantraine F., Vatish M., Sennstrom M., Olovsson M., *et al.* 2016. Predictive value of the sFlt-1:PIGF ratio in women with suspected preeclampsia. *N Engl J Med.* 374 (1): 13-22.

Zhong Y., Tuuli M., and Odibo AO. 2010. First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction. *Prenat Diagn.* 30(4):293-308.